Risk factors for developing medication-related osteonecrosis of the jaw when preserving the tooth that can be a source of infection in cancer patients receiving high-dose antiresorptive agents: a retrospective study.
Sakiko SoutomeMitsunobu OtsuruMaho MurataKota MorishitaKeisuke OmoriKoki SuyamaSaki HayashidaMasahiro UmedaToshiyuki SaitoPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2022)
It is recommended that teeth with apical lesion ≧ 3 mm, probing pocket depth ≧ 4 mm, or local infection symptoms are extracted before or as early as possible after beginning of medication in cancer patients receiving high-dose antiresorptive agent therapy to prevent the development of MRONJ.